For remission induction in Wegener granulomatosis, which medications are recommended?

For remission induction in Wegener granulomatosis, which medications are recommended?

• A. Azathioprine and prednisolone
• B. Cyclophosphamide, +/- rituximab and prednisolone
• C. Mycophenolate and leflunomide
• D. Methotrexate alone

Answer: (B)

Wegener granulomatosis, now more commonly referred to as granulomatosis with polyangiitis (GPA), is a type of vasculitis that primarily affects the respiratory tract and kidneys. The treatment aims to induce remission of the disease, particularly during severe manifestations. The recommended medications for remission induction typically include cyclophosphamide and glucocorticoids like prednisolone. Cyclophosphamide is a potent immunosuppressive agent that is particularly effective in controlling the aggressive nature of GPA, particularly when there are severe manifestations like renal involvement or lung disease. Additionally, the use of rituximab can be considered as an adjunct treatment, showing efficacy in certain patient populations and thus earning the recommendation as a combination therapy. This therapeutic approach targets both the inflammatory and autoimmune elements of the disease, helping to achieve a quicker and more sustained remission. Combining cyclophosphamide with prednisolone is well-supported by clinical evidence and guidelines, making it the standard treatment for patients who require urgent control of their symptoms. In contrast, while other agents such as azathioprine and mycophenolate are useful in maintenance therapy after remission has been achieved, they are not typically recommended for initial induction therapy in GPA due to their

Wegener granulomatosis, now more commonly referred to as granulomatosis with polyangiitis (GPA), is a type of vasculitis that primarily affects the respiratory tract and kidneys. The treatment aims to induce remission of the disease, particularly during severe manifestations.

The recommended medications for remission induction typically include cyclophosphamide and glucocorticoids like prednisolone. Cyclophosphamide is a potent immunosuppressive agent that is particularly effective in controlling the aggressive nature of GPA, particularly when there are severe manifestations like renal involvement or lung disease. Additionally, the use of rituximab can be considered as an adjunct treatment, showing efficacy in certain patient populations and thus earning the recommendation as a combination therapy.

This therapeutic approach targets both the inflammatory and autoimmune elements of the disease, helping to achieve a quicker and more sustained remission. Combining cyclophosphamide with prednisolone is well-supported by clinical evidence and guidelines, making it the standard treatment for patients who require urgent control of their symptoms.

In contrast, while other agents such as azathioprine and mycophenolate are useful in maintenance therapy after remission has been achieved, they are not typically recommended for initial induction therapy in GPA due to their